Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

277 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Reply from Authors re: Emmanuel S. Antonarakis, Howard I. Scher. Do Patients With AR-V7-Positive Prostate Cancer Benefit from Novel Hormonal Therapies? It All Depends on Definitions. Eur Urol 2017;71:4-6: Unsplicing a Conflict.
Steinestel J, Bernemann C, Schrader AJ, Lennerz JK. Steinestel J, et al. Among authors: lennerz jk. Eur Urol. 2017 Jan;71(1):6-7. doi: 10.1016/j.eururo.2016.08.071. Epub 2016 Sep 15. Eur Urol. 2017. PMID: 27641787 No abstract available.
Reply to Marcus V. Cronauer, Axel S. Merseburger, and M. Raschid Hoda's Letter to the Editor re: Christof Bernemann, Thomas J. Schnoeller, Manuel Luedeke, et al. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer. Eur Urol 2017;71:1-3.
Steinestel J, Bernemann C, Schrader AJ, Lennerz JK. Steinestel J, et al. Among authors: lennerz jk. Eur Urol. 2017 Apr;71(4):e107-e108. doi: 10.1016/j.eururo.2016.09.022. Epub 2016 Sep 16. Eur Urol. 2017. PMID: 27647434 No abstract available.
Allelic ratio of KRAS mutations in pancreatic cancer.
Lennerz JK, Stenzinger A. Lennerz JK, et al. Oncologist. 2015 Apr;20(4):e8-9. doi: 10.1634/theoncologist.2014-0408. Epub 2015 Mar 16. Oncologist. 2015. PMID: 25777349 Free PMC article.
Basket Trials: Just the End of the First Quarter.
Stenzinger A, Weichert W, Lennerz JK, Klauschen F. Stenzinger A, et al. Among authors: lennerz jk. J Clin Oncol. 2015 Sep 1;33(25):2823-4. doi: 10.1200/JCO.2015.62.1516. Epub 2015 Jul 13. J Clin Oncol. 2015. PMID: 26169614 No abstract available.
Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA.
Dagogo-Jack I, Brannon AR, Ferris LA, Campbell CD, Lin JJ, Schultz KR, Ackil J, Stevens S, Dardaei L, Yoda S, Hubbeling H, Digumarthy SR, Riester M, Hata AN, Sequist LV, Lennes IT, Iafrate AJ, Heist RS, Azzoli CG, Farago AF, Engelman JA, Lennerz JK, Benes CH, Leary RJ, Shaw AT, Gainor JF. Dagogo-Jack I, et al. Among authors: lennerz jk. JCO Precis Oncol. 2018;2018:PO.17.00160. doi: 10.1200/PO.17.00160. Epub 2018 Jan 23. JCO Precis Oncol. 2018. PMID: 29376144 Free PMC article.
277 results